On Chip Analysis of CNS Lymphoma in Cerebrospinal Fluid

Molecular profiling of central nervous system lymphomas in cerebrospinal fluid (CSF) samples can be challenging due to the paucicellular and limited nature of the samples. Presented herein is a microfluidic platform for complete CSF lymphoid cell analysis, including single cell capture in sub-nanoliter traps, and molecular and chemotherapeutic response profiling via on-chip imaging, all in less than one hour. The system can detect scant lymphoma cells and quantitate their kappa/lambda immunoglobulin light chain restriction patterns. The approach can be further customized for measurement of additional biomarkers, such as those for differential diagnosis of lymphoma subtypes or for prognosis, as well as for imaging exposure to experimental drugs.

[1]  W. Wilson,et al.  Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma , 2014, Haematologica.

[2]  S. Ponader,et al.  Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  W. Oyen,et al.  Theranostic applications of antibodies in oncology , 2014, Molecular oncology.

[4]  Ralph Weissleder,et al.  Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor , 2014, Scientific Reports.

[5]  Joshua M. Korn,et al.  Pharmacological and genomic profiling identifies NF-κB–targeted treatment strategies for mantle cell lymphoma , 2013, Nature Medicine.

[6]  Hakho Lee,et al.  Ascites analysis by a microfluidic chip allows tumor-cell profiling , 2013, Proceedings of the National Academy of Sciences.

[7]  U. Schlegel,et al.  The Diagnosis and Treatment of Primary CNS Lymphoma. , 2018, Deutsches Arzteblatt international.

[8]  X. Xie,et al.  Genome-Wide Detection of Single-Nucleotide and Copy-Number Variations of a Single Human Cell , 2012, Science.

[9]  D. Berry,et al.  From drug discovery to biomarker-driven clinical trials in lymphoma , 2012, Nature Reviews Clinical Oncology.

[10]  E. Thiel,et al.  Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  K. Ohshima,et al.  Comparison of CD20 expression in B‐cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment , 2012, Cancer science.

[12]  J. Villano,et al.  Age, gender, and racial differences in incidence and survival in primary CNS lymphoma , 2011, British Journal of Cancer.

[13]  J. Connor,et al.  Detection of cancer cells in the cerebrospinal fluid: current methods and future directions , 2011, Fluids and Barriers of the CNS.

[14]  J. Gratama,et al.  Central memory CD4+ T cells dominate the normal cerebrospinal fluid , 2011, Cytometry. Part B, Clinical cytometry.

[15]  A. Brunn,et al.  Diagnosis of leptomeningeal disease in diffuse large B‐cell lymphomas of the central nervous system by flow cytometry and cytopathology , 2010, European journal of haematology.

[16]  H. Prince,et al.  Mantle cell lymphoma with central nervous system involvement: frequency and clinical features , 2009, British journal of haematology.

[17]  Ofer Shpilberg,et al.  Role and prognostic significance of the Ki‐67 index in non‐Hodgkin's lymphoma , 2009, American journal of hematology.

[18]  Shigeo Nakamura,et al.  Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. , 2009, Blood.

[19]  Ryan R Brinkman,et al.  Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival. , 2009, Blood.

[20]  J. Briones,et al.  Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Staudt,et al.  Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways , 2008, Proceedings of the National Academy of Sciences.

[22]  Jun Luo,et al.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis , 2008, Modern Pathology.

[23]  Luke P. Lee,et al.  Dynamic single cell culture array. , 2006, Lab on a chip.

[24]  R. Liang,et al.  Secondary central nervous system involvement by non‐Hodgkin's lymphoma: The risk factors , 2006, Hematological oncology.

[25]  G. Trasimeni,et al.  Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma , 2006, Journal of Neuro-Oncology.

[26]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[27]  Luke P. Lee,et al.  Single-cell enzyme concentrations, kinetics, and inhibition analysis using high-density hydrodynamic cell isolation arrays. , 2006, Analytical chemistry.

[28]  J. Fridlyand,et al.  Gene expression and angiotropism in primary CNS lymphoma. , 2006, Blood.

[29]  I. Lossos,et al.  Prognostic biomarkers in diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Armitage,et al.  Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. Wilson,et al.  High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. , 2005, Blood.

[32]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[33]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[34]  M. Schabet.  Epidemiology of Primary CNS Lymphoma , 1999, Journal of Neuro-Oncology.

[35]  L. Bilston,et al.  Effects of Proteins, Blood Cells and Glucose on the Viscosity of Cerebrospinal Fluid , 1998, Pediatric Neurosurgery.

[36]  P. Mclaughlin,et al.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.

[37]  P. Faustmann,et al.  A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid , 1994, Journal of the Neurological Sciences.

[38]  A. Bluming,et al.  Central nervous system involvement in Burkitt's lymphoma. , 1970, Blood.

[39]  三好 寛明.  Comparison of CD20 expression in B-cell lymphoma between newly diagnosed, untreated cases and those after rituximab treatment , 2013 .

[40]  Kevin A. Pelphrey,et al.  Genome-Wide Detection of Single-Nucleotide and Copy-Number Variations of a Single Human Cell , 2012 .

[41]  K. Hoang-Xuan,et al.  A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. , 2006, Blood.

[42]  T. Kleine,et al.  Flow Cytometry of Cerebrospinal Fluid (CSF) Lymphocytes: Alterations of Blood/CSF Ratios of Lymphocyte Subsets in Inflammation Disorders of Human Central Nervous System (CNS) , 1999, Clinical chemistry and laboratory medicine.